Business Description
BioMerieux SA
ISIN : FR0013280286
Share Class Description:
FRA:EYWN: Ordinary SharesCompare
Compare
Traded in other countries / regions
BIM.France0RUG.UKBMXMF.USAEYWN.GermanyBIM.Austria IPO Date
2004-07-07Description
BioMĂ©rieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMĂ©rieux is headquartered in Marcy-l'Etoile, France.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 0.77 | |||||
| Interest Coverage | 183.19 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.12 | |||||
| Beneish M-Score | -2.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.6 | |||||
| 3-Year EBITDA Growth Rate | -2.7 | |||||
| 3-Year EPS without NRI Growth Rate | -0.2 | |||||
| 3-Year FCF Growth Rate | -29.5 | |||||
| 3-Year Book Growth Rate | 15.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.87 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.54 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.48 | |||||
| 9-Day RSI | 56.37 | |||||
| 14-Day RSI | 54.34 | |||||
| 6-1 Month Momentum % | 7.37 | |||||
| 12-1 Month Momentum % | -2.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.27 | |||||
| Days Inventory | 199.38 | |||||
| Days Sales Outstanding | 66.53 | |||||
| Days Payable | 52.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.84 | |||||
| Dividend Payout Ratio | 0.22 | |||||
| 3-Year Dividend Growth Rate | 64.8 | |||||
| Forward Dividend Yield % | 0.84 | |||||
| 5-Year Yield-on-Cost % | 2.8 | |||||
| Shareholder Yield % | 0.7 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.72 | |||||
| Operating Margin % | 15.4 | |||||
| Net Margin % | 10.81 | |||||
| FCF Margin % | 4.11 | |||||
| ROE % | 10.97 | |||||
| ROA % | 7.9 | |||||
| ROIC % | 10.27 | |||||
| ROC (Joel Greenblatt) % | 22.54 | |||||
| ROCE % | 12.34 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.42 | |||||
| Forward PE Ratio | 22.22 | |||||
| PE Ratio without NRI | 25.92 | |||||
| Shiller PE Ratio | 32.33 | |||||
| PEG Ratio | 2.88 | |||||
| PS Ratio | 3.19 | |||||
| PB Ratio | 3.11 | |||||
| Price-to-Tangible-Book | 4.59 | |||||
| Price-to-Free-Cash-Flow | 77.64 | |||||
| Price-to-Operating-Cash-Flow | 24.53 | |||||
| EV-to-EBIT | 23.93 | |||||
| EV-to-Forward-EBIT | 17.45 | |||||
| EV-to-EBITDA | 17.03 | |||||
| EV-to-Forward-EBITDA | 11.62 | |||||
| EV-to-Revenue | 3.24 | |||||
| EV-to-Forward-Revenue | 2.86 | |||||
| EV-to-FCF | 78.9 | |||||
| Price-to-Projected-FCF | 2.01 | |||||
| Price-to-DCF (Earnings Based) | 1.22 | |||||
| Price-to-DCF (FCF Based) | 5.19 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.98 | |||||
| Price-to-Graham-Number | 2.3 | |||||
| Price-to-Net-Current-Asset-Value | 15.79 | |||||
| Earnings Yield (Greenblatt) % | 4.18 | |||||
| FCF Yield % | 1.3 | |||||
| Forward Rate of Return (Yacktman) % | 10.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioMerieux SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,806.4 | ||
| EPS (TTM) (€) | 3.47 | ||
| Beta | 1.09 | ||
| Volatility % | 16.83 | ||
| 14-Day RSI | 54.34 | ||
| 14-Day ATR (€) | 0.735933 | ||
| 20-Day SMA (€) | 99.93 | ||
| 12-1 Month Momentum % | -2.63 | ||
| 52-Week Range (€) | 88.9 - 110.5 | ||
| Shares Outstanding (Mil) | 117.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioMerieux SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioMerieux SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioMerieux SA Frequently Asked Questions
What is BioMerieux SA(FRA:EYWN)'s stock price today?
The current price of FRA:EYWN is €101.40. The 52 week high of FRA:EYWN is €110.50 and 52 week low is €88.90.
When is next earnings date of BioMerieux SA(FRA:EYWN)?
The next earnings date of BioMerieux SA(FRA:EYWN) is 2025-03-14 Est..
Does BioMerieux SA(FRA:EYWN) pay dividends? If so, how much?
The Dividend Yield %  of BioMerieux SA(FRA:EYWN) is 0.84% (As of Today), Highest Dividend Payout Ratio of BioMerieux SA(FRA:EYWN) was 0.26. The lowest was 0.05. And the median was 0.15. The  Forward Dividend Yield % of BioMerieux SA(FRA:EYWN) is 0.84%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers